UCL- Saint Luc

Brussels B-1200

1 studies enrolling now · 16 studies all time

What they study most

Acquired Immunodeficiency Syndrome, Adolescent, Aneurysmal Subarachnoid Hemorrhage, Candidemia, Carcinoma, Hepatocellular, Child, Chronic Graft Versus Host Disease, Chronic Hepatitis C Infection, Chronic Lymphocytic Leukemia, Dedifferentiated Liposarcoma, Diffuse Large B-cell Lymphoma, Drug Resistant Epilepsy

Studies at this site

• A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer — Recruiting now
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — Recruiting now
• Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours — Completed
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. — Completed
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma — Completed
• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma — Stopped early
• Selinexor Treatment of Refractory Myeloma — Completed
• Selinexor in Advanced Liposarcoma — Completed
• Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour — Completed
• Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma — Completed
• Plaque Psoriasis Study in Pediatric Subjects — Completed
• CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension — Completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage — Stopped early
• Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed
• A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C — Completed